Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 30 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-200.81 Insider Own0.50% Shs Outstand- Perf Week3.72%
Market Cap2.72M Forward P/E- EPS next Y-3.13 Insider Trans-73.97% Shs Float5.10M Perf Month-35.21%
Income-23.51M PEG- EPS next Q-1.23 Inst Own8.88% Short Float / Ratio1.27% / 0.06 Perf Quarter-61.87%
Sales0.00M P/S- EPS this Y99.50% Inst Trans- Short Interest0.06M Perf Half Y-91.67%
Book/sh-0.83 P/B- EPS next Y69.50% ROA-303.48% Target Price20.50 Perf Year-99.70%
Cash/sh0.18 P/C2.99 EPS next 5Y- ROE-798.16% 52W Range0.48 - 295.20 Perf YTD-99.40%
Dividend- P/FCF- EPS past 5Y10.22% ROI-1374.17% 52W High-99.82% Beta0.74
Dividend %- Quick Ratio0.21 Sales past 5Y0.00% Gross Margin- 52W Low10.42% ATR0.10
Employees7 Current Ratio0.21 Sales Q/Q- Oper. Margin0.00% RSI (14)36.63 Volatility14.87% 17.77%
OptionableNo Debt/Eq- EPS Q/Q98.94% Profit Margin- Rel Volume0.33 Prev Close0.50
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume1.06M Price0.53
Recom1.00 SMA20-15.59% SMA50-40.08% SMA200-93.41% Volume351,885 Change6.77%
Nov-29-23 08:15AM
Nov-09-23 04:10PM
Nov-03-23 07:55AM
Nov-02-23 08:15AM
Oct-31-23 08:15AM
08:15AM Loading…
Oct-25-23 08:15AM
Oct-24-23 08:15AM
Sep-26-23 08:15AM
Sep-19-23 08:15AM
Sep-05-23 08:15AM
Aug-28-23 08:15AM
Aug-14-23 08:15AM
Aug-13-23 08:55AM
Aug-10-23 04:10PM
Jul-31-23 04:15PM
08:15AM Loading…
Jul-24-23 08:15AM
Jul-19-23 08:00AM
Jul-17-23 06:00AM
Jul-10-23 08:15AM
Jun-28-23 08:15AM
Jun-26-23 08:15AM
Jun-21-23 04:15PM
Jun-16-23 08:15AM
Jun-13-23 08:15AM
Jun-01-23 08:15AM
May-31-23 08:00AM
May-22-23 08:15AM
May-04-23 04:10PM
Apr-24-23 08:15AM
Apr-19-23 08:15AM
08:15AM Loading…
Apr-12-23 08:15AM
Apr-11-23 08:15AM
Apr-10-23 08:30AM
Apr-06-23 08:30AM
Apr-03-23 08:30AM
Mar-22-23 08:30AM
Mar-18-23 10:29AM
Mar-16-23 04:10PM
Mar-08-23 08:00AM
Mar-07-23 08:00AM
Mar-01-23 08:30AM
Feb-13-23 08:30AM
Jan-26-23 08:41AM
Jan-19-23 09:00AM
Jan-12-23 11:00AM
Jan-11-23 09:00AM
Dec-14-22 09:00AM
Nov-28-22 09:00AM
Nov-10-22 04:10PM
Oct-31-22 09:00AM
Oct-06-22 08:00AM
Sep-30-22 08:37AM
Sep-29-22 09:00AM
Aug-15-22 04:10PM
Aug-11-22 09:00AM
Aug-04-22 09:00AM
Aug-01-22 04:00PM
Jun-28-22 08:00AM
Jun-16-22 08:00AM
May-12-22 04:05PM
Apr-27-22 08:30AM
Apr-26-22 08:30AM
Apr-12-22 08:30AM
Mar-24-22 04:05PM
Mar-23-22 08:30AM
Mar-10-22 08:30AM
Mar-08-22 08:30AM
Mar-07-22 08:30AM
Feb-22-22 08:00AM
Jan-26-22 09:00AM
Jan-24-22 09:00AM
Dec-14-21 09:00AM
Nov-18-21 09:00AM
Nov-10-21 04:15PM
Oct-25-21 09:00AM
Sep-27-21 01:08PM
Sep-07-21 09:00AM
Aug-11-21 04:12PM
Aug-09-21 08:00AM
Jul-28-21 09:00AM
Jul-08-21 11:20AM
Jul-07-21 08:45AM
Jul-02-21 04:05PM
Jun-30-21 12:06AM
Jun-29-21 05:25PM
Jun-23-21 09:35AM
Jun-08-21 05:07PM
Jun-04-21 09:15AM
May-26-21 08:00AM
May-12-21 04:10PM
Apr-28-21 08:00AM
Apr-15-21 08:00AM
Apr-06-21 08:15AM
Mar-29-21 07:37AM
Mar-26-21 08:40AM
Mar-25-21 04:30PM
Mar-17-21 06:02PM
Mar-15-21 08:00AM
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm's product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDMAN SACHS GROUP INC10% OwnerNov 08Sale0.7172,87451,741397,954Nov 13 07:29 PM